For the Moment, Pharmion Helps Burnish Biotech's Image

Biotech's unique volatility and the intuition that risk will be rewarded when science and business manage to click for the benefit of patients are also powerful incentives--including for drugs that fall under Pharma's radar. That dynamic seems to be playing out for the moment for Pharmion--the rare standout in the score of recent biopharm IPOs--as it prepares to roll out its recently approved drug, Vidaza.

A story in The Wall Street Journal last month highlighted the relatively poor rate of return provided by biotech investments relative to the Dow Jones Industrial Average or even T-bonds. But the WSJ failed to capture the notion that the numbers suggest that the overall rate of return for the sector isn't the only driver of investor interest. Biotech's unique volatility and the intuition that risk will be rewarded when science and business manage to click for the benefit of patients are also powerful incentives. Hefty returns therefore should be possible--including for drugs aimed at small markets that fall under the radar of Big Pharma. And that dynamic seems to be playing out, at least for the moment, as Pharmion Corp. prepares to roll out its recently approved drug, azacitidine (Vidaza).

A hematology/oncology-focused specialty pharma in-licensor, Pharmion is the only standout, along with Eyetech Pharmaceuticals Inc. , in the score...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.